MX2009010223A - Antagonistas del receptor de adenosina a2a. - Google Patents
Antagonistas del receptor de adenosina a2a.Info
- Publication number
- MX2009010223A MX2009010223A MX2009010223A MX2009010223A MX2009010223A MX 2009010223 A MX2009010223 A MX 2009010223A MX 2009010223 A MX2009010223 A MX 2009010223A MX 2009010223 A MX2009010223 A MX 2009010223A MX 2009010223 A MX2009010223 A MX 2009010223A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- compounds
- disease
- employed
- adenosine
- Prior art date
Links
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 title abstract 2
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000004761 fibrosis Effects 0.000 abstract 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 102000007471 Adenosine A2A receptor Human genes 0.000 abstract 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 abstract 1
- 206010001540 Akathisia Diseases 0.000 abstract 1
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 208000014094 Dystonic disease Diseases 0.000 abstract 1
- 208000027776 Extrapyramidal disease Diseases 0.000 abstract 1
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 208000001431 Psychomotor Agitation Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 230000003920 cognitive function Effects 0.000 abstract 1
- 208000010118 dystonia Diseases 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 230000000737 periodic effect Effects 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90910607P | 2007-03-30 | 2007-03-30 | |
| US12/056,423 US7723343B2 (en) | 2007-03-30 | 2008-03-27 | Adenosine A2A receptor antagonists |
| US12/056,403 US7691869B2 (en) | 2007-03-30 | 2008-03-27 | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity |
| PCT/US2008/058544 WO2008121748A2 (en) | 2007-03-30 | 2008-03-28 | Adenosine a2a receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009010223A true MX2009010223A (es) | 2009-10-26 |
Family
ID=39795488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009010223A MX2009010223A (es) | 2007-03-30 | 2008-03-28 | Antagonistas del receptor de adenosina a2a. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7723343B2 (enExample) |
| EP (1) | EP2129220A4 (enExample) |
| JP (1) | JP2010523497A (enExample) |
| KR (1) | KR20100014397A (enExample) |
| CN (1) | CN101652067A (enExample) |
| AU (1) | AU2008232690A1 (enExample) |
| BR (1) | BRPI0808438A2 (enExample) |
| CA (1) | CA2680075A1 (enExample) |
| IL (1) | IL201234A0 (enExample) |
| MX (1) | MX2009010223A (enExample) |
| NZ (1) | NZ578720A (enExample) |
| WO (1) | WO2008121748A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007263726A1 (en) * | 2006-06-27 | 2008-01-03 | Biovitrum Ab (Publ) | Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists |
| SI2299821T1 (sl) | 2008-06-10 | 2016-03-31 | Abbvie Inc. | Triciklične spojine |
| JP2012510523A (ja) * | 2008-12-03 | 2012-05-10 | プレシディオ ファーマシューティカルズ インコーポレイテッド | Ｈｃｖｎｓ５ａの阻害剤 |
| US8859566B2 (en) | 2009-03-13 | 2014-10-14 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
| PL2506716T3 (pl) * | 2009-12-01 | 2017-10-31 | Abbvie Inc | Nowe związki tricykliczne |
| US8785639B2 (en) | 2009-12-01 | 2014-07-22 | Abbvie Inc. | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof |
| WO2011101861A1 (en) | 2010-01-29 | 2011-08-25 | Msn Laboratories Limited | Process for preparation of dpp-iv inhibitors |
| JP5843869B2 (ja) * | 2010-09-24 | 2016-01-13 | アドヴィナス・セラピューティックス・リミテッド | アデノシン受容体拮抗薬としての縮合三環化合物 |
| WO2012149280A2 (en) * | 2011-04-29 | 2012-11-01 | Abbott Laboratories | Novel tricyclic compounds |
| WO2015027431A1 (en) | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
| US20170129902A1 (en) | 2015-10-16 | 2017-05-11 | Abbvie Inc. | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-alpha]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| JP7023933B2 (ja) * | 2016-08-19 | 2022-02-22 | ブリストル－マイヤーズ スクイブ カンパニー | セコ－シクロプロパピロロインドール化合物、その抗体－薬物コンジュゲート、ならびに製造および使用方法 |
| RS63557B1 (sr) * | 2017-03-30 | 2022-10-31 | iTeos Belgium SA | Derivati 2-okso-tiazola kao inhibitori a2a i jedinjenja za upotrebu u lečenju kancera |
| US11312719B2 (en) | 2018-11-30 | 2022-04-26 | Merck Sharp & Dohme Corp. | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| AU7237294A (en) | 1993-07-27 | 1995-02-28 | Kyowa Hakko Kogyo Co. Ltd. | Remedy for parkinson's disease |
| IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| MXPA02011625A (es) | 2000-05-26 | 2003-03-27 | Schering Corp | Antagonistas receptores de adenosina a2a. |
| AR037243A1 (es) | 2001-10-15 | 2004-11-03 | Schering Corp | Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
| ATE453647T1 (de) | 2001-11-30 | 2010-01-15 | Schering Corp | Adenosin a2a rezeptor antagonisten |
| HK1082662A1 (zh) | 2002-05-30 | 2006-06-16 | King Pharmaceuticals Research And Development Inc. | 具有三环吡唑并三唑并嘧啶环结构的制药活性化合物及其使用方法 |
| US20060128694A1 (en) | 2002-12-19 | 2006-06-15 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| EP1622912B1 (en) | 2003-04-23 | 2009-05-27 | Schering Corporation | 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists |
| US7709492B2 (en) | 2004-04-21 | 2010-05-04 | Schering Corporation | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists |
| CA2622741A1 (en) | 2005-09-19 | 2007-03-29 | Schering Corporation | 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists |
| AR056080A1 (es) | 2005-09-23 | 2007-09-19 | Schering Corp | 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine |
-
2008
- 2008-03-27 US US12/056,423 patent/US7723343B2/en not_active Expired - Fee Related
- 2008-03-27 US US12/056,403 patent/US7691869B2/en not_active Expired - Fee Related
- 2008-03-28 WO PCT/US2008/058544 patent/WO2008121748A2/en not_active Ceased
- 2008-03-28 MX MX2009010223A patent/MX2009010223A/es active IP Right Grant
- 2008-03-28 NZ NZ578720A patent/NZ578720A/en not_active IP Right Cessation
- 2008-03-28 CN CN200880010845A patent/CN101652067A/zh active Pending
- 2008-03-28 CA CA002680075A patent/CA2680075A1/en not_active Abandoned
- 2008-03-28 KR KR1020097019161A patent/KR20100014397A/ko not_active Withdrawn
- 2008-03-28 BR BRPI0808438-6A patent/BRPI0808438A2/pt not_active IP Right Cessation
- 2008-03-28 JP JP2010501235A patent/JP2010523497A/ja not_active Withdrawn
- 2008-03-28 EP EP08744527A patent/EP2129220A4/en not_active Withdrawn
- 2008-03-28 AU AU2008232690A patent/AU2008232690A1/en not_active Abandoned
-
2009
- 2009-09-29 IL IL201234A patent/IL201234A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0808438A2 (pt) | 2014-07-29 |
| NZ578720A (en) | 2011-01-28 |
| US7691869B2 (en) | 2010-04-06 |
| WO2008121748A3 (en) | 2009-09-11 |
| CN101652067A (zh) | 2010-02-17 |
| AU2008232690A1 (en) | 2008-10-09 |
| US7723343B2 (en) | 2010-05-25 |
| WO2008121748A2 (en) | 2008-10-09 |
| KR20100014397A (ko) | 2010-02-10 |
| EP2129220A4 (en) | 2010-12-29 |
| IL201234A0 (en) | 2010-05-31 |
| US20080242672A1 (en) | 2008-10-02 |
| US20080242673A1 (en) | 2008-10-02 |
| AU2008232690A2 (en) | 2009-12-10 |
| EP2129220A2 (en) | 2009-12-09 |
| JP2010523497A (ja) | 2010-07-15 |
| CA2680075A1 (en) | 2008-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009010223A (es) | Antagonistas del receptor de adenosina a2a. | |
| SG179120A1 (en) | Novel compounds | |
| CL2009000953A1 (es) | Compuestos derivados de 2-imino-3-metil-pirrolo pirimidinona, composicion farmaceutica, util para inhibir la beta-secretasa, destinado al tratamiento de la enfermedad de alzheimer, sindrome de down, parkinson, perdida de la memoria, demencia, accidente cerebrovascular, microgliosis e inflamacion cerebral, glaucoma amiloidosis, diabetes tipo ii, entre otras. | |
| ECSP13012708A (es) | Compuestos y su uso como inhibidores de bace | |
| MX2009009447A (es) | Dihidro y tetrahidro oxazolopirimidinonas sustituidas, preparacion y uso de las mismas. | |
| MX340807B (es) | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. | |
| UA89830C2 (ru) | Кристаллическая модификация iv пираклостробина, способы ее получения, композиция для защиты растений и применение | |
| MX2020012825A (es) | Compuestos multiciclicos y metodos de uso de los mismos. | |
| UA101493C2 (ru) | Производные азетидина и циклобутана как ингибиторы jak | |
| WO2009127642A3 (en) | Use of lrrk2 inhibitors for neurodegenerative diseases | |
| MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
| MX2009007713A (es) | Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas. | |
| CU20110106A7 (es) | Nuevos compuestos 578 | |
| EA200971050A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
| UA93531C2 (en) | Novel hydrogen sulfate salt | |
| NZ592571A (en) | Aryl piperazine and their use as alpha2c antagonists | |
| TW200745135A (en) | Therapeutic agents | |
| TW200621716A (en) | Novel compounds | |
| MX2011008850A (es) | Derivados de piperidina como antagonistas del receptor de neuroquinina 3 (nk3). | |
| NZ593279A (en) | Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors | |
| TW200611701A (en) | Novel compounds | |
| TN2012000191A1 (en) | Quinuclidine compounds as alpha-7nicotinic acetylcholine receptor ligands | |
| ZA201000394B (en) | Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds | |
| TW200716564A (en) | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | |
| MY179041A (en) | Crystalline forms of a 3-carboxypropyl-aminotetralin compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |